Search - tctmd.com

Displaying 61 - 80 of 108

Sort: Relevancy | Date

News Daily News

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

Yael L. Maxwell

June 23, 2022

News Daily News

Infertility in Women Linked to Subsequent Risk of HFpEF

L.A. McKeown

April 19, 2022

News Daily News

Best Exercise for Heart Health? Some Hints of Intensity’s Role

Michael O'Riordan

December 02, 2021

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Todd Neale

November 15, 2021

Presentation TCT 2021

Leading with Evidence: Latest Data on Renal Denervation

Presenter: NULL

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

Presentation TCT 2021

Latest Evidence in the SPYRAL-HTN Clinical Program

Presenter: NULL

November 05, 2021

Presentation TCT 2021

Scanning Laser Angioscopy: A New High-Resolution Multimodal Platform for Intravascular Diagnosis and Therapy

Presenter: NULL

November 05, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Todd Neale

October 13, 2021

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

Caitlin E. Cox

October 11, 2021

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

News Daily News

Multivessel PCI May Be Less Suitable for Elderly STEMI Patients: NCDR Data

Caitlin E. Cox

August 20, 2021

News Daily News

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

Michael O'Riordan

August 17, 2021

News Conference News ESC Heart Failure 2021

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

Shelley Wood

June 30, 2021

News Conference News EuroPCR 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

Michael O'Riordan

May 18, 2021

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

News Daily News

Did Regional Differences Muddy Results in COMMANDER-HF?

L.A. McKeown

February 04, 2021

News Daily News

CABG Loses Survival Advantage in Women at 10 Years: SYNTAXES

Yael L. Maxwell

August 20, 2020

News Daily News

New EXCEL Analysis Reignites Debate Over PCI for Left Main CAD

Michael O'Riordan

June 01, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Advertisement

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

Infertility in Women Linked to Subsequent Risk of HFpEF

Best Exercise for Heart Health? Some Hints of Intensity’s Role

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Leading with Evidence: Latest Data on Renal Denervation

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Latest Evidence in the SPYRAL-HTN Clinical Program

Scanning Laser Angioscopy: A New High-Resolution Multimodal Platform for Intravascular Diagnosis and Therapy

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Multivessel PCI May Be Less Suitable for Elderly STEMI Patients: NCDR Data

Endpoint Reporting in Medical Journals Needs to Be Revamped: Review

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

Elective Revascularization, Better Long-term Survival: Meta-analysis

FDA Approves Evinacumab for Rare Homozygous FH

Did Regional Differences Muddy Results in COMMANDER-HF?

CABG Loses Survival Advantage in Women at 10 Years: SYNTAXES

New EXCEL Analysis Reignites Debate Over PCI for Left Main CAD

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content